HIV/AIDS - Research and Palliative Care

HIV/AIDS - Research and Palliative Care is an international, peer-reviewed, open-access journal published by Dove Medical Press in Auckland, New Zealand, and it has appeared without interruption since the first volume of 2009.《HIV/AIDS - Research and Palliative Care》是新西兰奥克兰 Dove Medical Press 出版的国际同行评审开放获取期刊，自 2009 年第 1 卷起连续出版，未曾休刊。

Its territory is the whole arc of HIV medicine, running from viral epidemiology and antiretroviral treatment through palliative care and patient-reported outcomes to the health policy that governs access.刊物覆盖 HIV 医学的整条脉络，从病毒流行病学与抗逆转录病毒治疗，经姑息治疗与患者报告结局，一直到决定药物可及的卫生政策。

Clarivate's 2025 metrics put the Journal Impact Factor at 2.4 and the five-year value at 2.5, and a CiteScore of 3.6 places the title in the second quartile of that measure.科睿唯安（Clarivate）的 2025 年指标给出影响因子 2.4 与五年影响因子 2.5，CiteScore 为 3.6，按该项指标列第二四分位。

Scope

• The stated remit is advances in HIV research, the clinical progression of infection and the management options that follow from it, with antiviral treatment and palliative care named among them.公开定位是 HIV 研究的进展、感染的临床进程以及由此衍生的处置方案，抗病毒治疗与姑息治疗都被点名列入。

• Public health policy to control viral spread sits in the scope beside laboratory and bedside work, which keeps prevention and treatment inside a single frame rather than two.控制病毒传播的公共卫生政策与实验室工作、临床工作并列写进范围，预防与治疗因此留在同一个框架内，没有分成两块。

• Epidemiology of HIV spread and of drug resistance heads the topic list, which runs to ten items in all.选题清单的第一项是 HIV 传播与耐药性的流行病学，整份清单共十条。

• Diagnostics come next, with early detection and the monitoring of treated patients counted as research questions in their own right instead of routine service detail.随后是诊断，早期发现与治疗过程中的监测被当作独立的研究问题，没有降格为常规服务细节。

• Identification of viral targets and the development of agents with novel mechanisms of action make up the discovery end of the remit, which keeps bench virology inside the journal.病毒靶点的识别与全新作用机制药物的开发，构成这份范围里的发现端，实验室病毒学因此留在刊内。

• Optimal clinical use of existing antivirals is named as a separate item, combination therapies included, so regimen design and pharmacology both fall inside the scope.现有抗病毒药物的最佳临床用法单列一条，联合治疗包含在内，方案设计与药理学因此都落在范围里。

• Vaccine development appears as its own item rather than folded into prevention, and the scope page sets no narrower limit on it.疫苗开发单独立项，没有并入预防，范围页也没有给它附加更窄的限定。

• Management and treatment of the disorders that accompany AIDS, palliative care among them, turns the second half of the title into an operating category.艾滋病患者合并症的处理与治疗，姑息治疗也在其中，把刊名后半段变成了可操作的栏目。

• Adherence, quality of life and patient satisfaction are listed as outcomes that submissions may measure and report across different care settings.依从性、生活质量与患者满意度被列为投稿可以测量并报告的结局，也允许在不同照护场景之间比较。

• Consumer and patient education, together with health literacy programmes, widens the readership beyond clinicians to the people the research is meant to serve.面向消费者与患者的教育，连同健康素养项目，把读者面从临床医生扩展到研究本该服务的人群。

• Health economics and public health policy close the list, which stays short and clinical rather than encyclopaedic in the manner of a general medical title.卫生经济学与公共卫生政策收束整份清单，清单本身简短而偏临床，不像综合医学刊那样铺成百科。

• Original research and basic science are accepted, as are clinical and epidemiological studies, and those four labels cover most of what the journal prints.原创研究与基础科学都在受理之列，临床研究与流行病学研究同样如此，这四类标签覆盖了刊物印行的大部分内容。

• Reviews and evaluations are considered, and so are guidelines, expert opinion and commentary, which gives policy-facing writing a route into the journal.综述与评估类稿件可以投，指南、专家意见与评论同样可以，面向政策的写作因此有了入口。

• Case reports and extended reports complete the manuscript types named on the scope page, which carries a revision date of 16 July 2025.病例报告与长篇幅报告补全了范围页点明的稿件类型，该页标注的修订日期为 2025 年 7 月 16 日。

• The title pairs research with palliative care, and the scope keeps symptom control and end-of-life questions in the same submission stream as virology.刊名把研究与姑息治疗并置，范围也把症状控制与临终议题留在与病毒学相同的投稿流里。

History

• Dove Medical Press launched the title from Auckland in 2009, and the first volume carried five papers across the calendar year.Dove Medical Press 于 2009 年在奥克兰创办本刊，第 1 卷全年只登了 5 篇论文。

• That publisher had itself started in 2003 as an open-access-only house, so the journal never ran a subscription edition at any point.这家出版方本身在 2003 年成立，只做开放获取，本刊因此从未出过订阅版。

• Gold open access has been the only model since volume one, with costs carried by authors instead of subscribers and no paywall at any stage.从第 1 卷起就只有金色开放获取一种模式，费用由作者承担，不向订阅机构收取，任何环节都没有付费墙。

• PubMed and PubMed Central have covered it from 2009, indexed under the abbreviation HIV AIDS (Auckl), and the NLM record keeps the older punctuation of the title.PubMed 与 PubMed Central 从 2009 年起收录，缩写为 HIV AIDS (Auckl)，美国国家医学图书馆的记录保留了刊名的旧式标点。

• Scopus and Embase both began indexing in 2011, and the metrics page also lists the Directory of Open Access Journals and OAIster among the services that record it.Scopus 与 Embase 都在 2011 年开始收录，指标页还把开放获取期刊目录（DOAJ）与 OAIster 列入收录服务。

• Taylor & Francis, the academic publishing division of Informa, acquired Dove Medical Press in 2017, and the journal moved into the group with its imprint intact.Informa 旗下学术出版部门 Taylor & Francis 于 2017 年收购 Dove Medical Press，本刊随之进入该集团，出版品牌原样保留。

• Every page now ends with a notice that Dove Medical Press Ltd is part of Taylor & Francis Group, the academic publishing division of Informa PLC.如今每个页面末尾都注明 Dove Medical Press Ltd 隶属 Taylor & Francis Group，即 Informa PLC 的学术出版部门。

• Clarivate lists the journal in the Emerging Sources Citation Index, in the Infectious Diseases category at 80 of 141 titles and in the third quartile.科睿唯安（Clarivate）把本刊列入新兴来源引文索引，传染病类目 141 种刊物中排第 80 位，属第三四分位。

• Impact Factor readings are 1.5 for 2023, 1.8 for 2024 and 2.4 for 2025, the last against a five-year figure of 2.5.影响因子的读数是 2023 年 1.5，2024 年 1.8，2025 年 2.4，最后一年对应的五年值为 2.5。

• One volume is closed each calendar year, so volume 18 covers 2026 and volume 1 covers 2009, with no gap in the sequence.每个日历年结成一卷，第 18 卷对应 2026 年，第 1 卷对应 2009 年，编号中间没有断档。

• No issues are assembled. A paper goes online with an article number inside the current volume, and Crossref records for the journal leave the issue field empty.刊物不编期，论文带文章编号进入当年卷内，Crossref 记录里的期号字段一律为空。

• Recent papers carry identifiers such as 18:655596, while earlier volumes still show page ranges such as 697-706 in volume 12 for 2020.近年论文的标识形如 18:655596，早期各卷仍标页码区间，2020 年第 12 卷的 697 至 706 页即是一例。

• The site lists 677 articles in all, with 112 in 2021 as the busiest year, 42 in 2024 and 37 in 2025.站点累计列出 677 篇论文，2021 年以 112 篇为最多年份，2024 年为 42 篇，2025 年为 37 篇。

• Usage stands at 103,848 annual downloads and views, with 1,280 citations in total, a CiteScore of 3.6, an SJR of 0.623 and a SNIP of 0.990.年度下载与浏览量为 103,848 次，总被引 1,280 次，CiteScore 为 3.6，SJR 为 0.623，SNIP 为 0.990。

Editors

• Olubunmi Akindele Ogunrin is Editor-in-Chief and works as a consultant neurologist at the University Hospitals of North Midlands NHS Trust in Stoke-on-Trent, England.主编为（Olubunmi Akindele Ogunrin），他在英格兰特伦特河畔斯托克的北米德兰兹大学医院 NHS 信托（University Hospitals of North Midlands NHS Trust）任神经科顾问医师。

• Until recently he was professor of internal medicine and neurology at the University of Benin and an honorary consultant at the University Teaching Hospital in Nigeria, and he holds a PhD from the University of Liverpool.此前他是贝宁大学（University of Benin）内科学与神经病学教授，兼任尼日利亚大学教学医院（University Teaching Hospital）荣誉顾问医师，博士学位得自利物浦大学（University of Liverpool）。

• His research covers the cognitive neurology of HIV and of epilepsy, including how often cognitive impairment appears in HIV patients and what form it takes.他的研究覆盖 HIV 与癫痫的认知神经病学，包括 HIV 患者认知损伤的出现频率与表现形式。

• He has examined how highly active antiretroviral therapy affects cognitive performance, and published a meta-analysis linking cognitive impairment to quality of life in HIV.他考察过高效抗逆转录病毒治疗对认知表现的影响，并发表过一项把 HIV 患者的认知损伤与生活质量联系起来的荟萃分析。

• The editorial board lists 16 members, 13 of whom work at institutions in the United States.编委会名单共 16 人，其中 13 人在美国机构任职。

• The rest sit in Iran, Ethiopia and Puerto Rico, represented by Saeed Amini of Khomein University of Medical Sciences, Zelalem Addis of the University of Gondar and Carmen D. Zorrilla of the University of Puerto Rico.其余席位分属伊朗、埃塞俄比亚与波多黎各，代表分别是霍梅因医科大学（Khomein University of Medical Sciences）的（Saeed Amini），贡德尔大学（University of Gondar）的（Zelalem Addis），波多黎各大学（University of Puerto Rico）的（Carmen D. Zorrilla）。

• Virology and drug discovery are well represented on the board, with Raymond F. Schinazi of Emory and Thomas Quinn of Johns Hopkins among the members.病毒学与药物研发在编委中有明显分量，埃默里大学（Emory University）的（Raymond F. Schinazi）与约翰斯·霍普金斯大学（Johns Hopkins University）的（Thomas Quinn）都在名单里。

• Paediatrics and pathology appear on the list, and so do neuroscience and statistics, which suits a remit running from viral targets to health services.名单里既有儿科与病理学，也有神经科学与统计学，与从病毒靶点延伸到卫生服务的范围相称。

• Review is single-anonymous, still described on the guidelines page as single-blind, and referees are asked to return comments within 10 business days.评审采用单向匿名，指南页仍沿用单盲的旧称，审稿人被要求在 10 个工作日内交回意见。

• The journal reports 42 days from submission to a first editorial decision, three days from acceptance to publication and a 33 per cent acceptance rate.刊方公布的数字是投稿到首次编辑决定平均 42 天，录用到上线平均 3 天，录用率 33%。

• Meta-analyses are no longer considered for publication, a restriction that appears on the scope page beside the topic list.荟萃分析不再受理，这条限制写在范围页的选题清单旁边。

• An Accelerated Publication service is offered for manuscripts that need to move quickly, and the journal is a member of COPE.需要快速推进的稿件可以走加速出版服务，刊物同时是出版伦理委员会（COPE）的成员。